- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01796236
Clinical and Health Economic Evaluation With a New Baha® Abutment Combined With a Minimally Invasive Surgical Technique
Clinical and Health Economic Evaluation of a New Baha® Abutment, With a Minimally Invasive Surgical Technique. An International Multicentre, Open, Randomised, Comparative, Parallel Group, Investigation. 1y Investigation, 2y Follow-up
To demonstrate that the minimally invasive surgical procedure in combination with the use of the Cochlear Baha BA400 abutment is associated with a reduction of inflammation/infection, overgrowth, pain and numbness at the site of implantation compared to the traditional surgical procedure in combination with the use of the standard Baha abutment (Cochlear Baha BA300 Abutment).
To demonstrate that the minimally invasive surgical procedure in combination with the use of the Cochlear Baha BA400 abutment is associated with a reduction in direct medical costs, due to shorter surgical procedures, faster wound healing and less complications compared to the traditional surgical procedure in combination with the use of the standard Baha abutment (Cochlear Baha BA300 Abutment).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Despite extensive soft tissue reduction, the most common complications associated with Baha implants are related to adverse skin reactions around the abutment. The reduction of the skin also adds complexity to the surgical procedure that is otherwise a routine type of skin incision. A less invasive surgical technique avoiding reducing the thickness of the skin would render a simpler and shorter procedure and would be aesthetically appealing to the patients, as permanent hair removal in the area around the abutment would not be required. Faster healing and less numbness (sensory loss/ paraesthesia) at the implant site may also be expected if the soft tissue thickness is left intact.
The Cochlea Baha BA300 Abutment together with a surgical procedure that includes soft tissue reduction was CE marked in April 2010. The test abutment, Cochlear Baha BA400, together with a surgical procedure that does not require soft tissue reduction was CE marked in June 2012.
The rationale behind this investigation was to make a 'head-to-head' comparison between the BA300 and BA400 Abutment and the associated surgical techniques in order to collect information regarding complications (inflammation/infection, numbness and pain), aesthetic outcome and utilisation of direct medical cost associated with surgery.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Toulouse, France, 31059
- Service ORL
-
-
-
-
-
Breda, Netherlands
- KNO arts, Amphia Ziekenhuis
-
Deventer, Netherlands
- Deventer Ziekenhuis
-
Eindhoven, Netherlands, 5623
- Dept. ENT/KNO
-
Maastricht, Netherlands, 6202
- NT department
-
-
-
-
-
Valencia, Spain, ES-46010
- Otorhinolaryngology, Hospital Clinico Universitario De Valencia
-
-
-
-
-
Gothenburg, Sweden, 411 35
- ENT Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Eligible for the Baha system
- Signed informed consent
Exclusion Criteria:
- Patient scheduled for simultaneously bilateral implant surgery
- Uncontrolled diabetes as judged by the investigator
- Condition that could jeopardize osseointegration and/or wound healing, e.g. osteoporosis, psoriasis and use of corticosteroids
- Unable to follow the cleaning instruction
- Unable to follow investigational procedures, e.g. to complete quality of life scales
- Participation in another investigation with pharmaceuticals and/or device
- Condition that may have an impact on the outcome of the investigation as judged by the investigator
- Suitable implant position for the 4 mm implant not found during surgery due to insufficient bone quality and/or bone thickness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Minimally invasive surgery and BA400
This arm involves no soft tissue reduction around the BA400 implant.
|
The Cochlear Baha BA400 Abutment has been designed with a concave shape at the lower aspect of the abutment.
The abutment is made of commercially pure titanium and is coated with a hydroxyapatite layer on the entire soft tissue-contacting surface of the abutment up to 3 mm below the top surface (2 mm below the top surface on 6 mm abutments).
|
Active Comparator: Traditional surgery and BA300
This arm involves traditional soft tissue reduction around the BA300 implant
|
The BA300 abutment is made of commercially pure titanium and is available in two different lengths (6 mm and 9 mm).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Local Adverse Events as a Measure of Safety and Tolerability
Time Frame: 12 months
|
Combined endpoint of infection/inflammation, overgrowth, pain and numbness will be evaluated, as the sum of the following four events:
|
12 months
|
Number of Participants With Local Adverse Events as a Measure of Safety and Tolerability
Time Frame: 36 months
|
Combined endpoint of infection/inflammation, overgrowth, pain and numbness will be evaluated, as the sum of the following four events:
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Surgery Time
Time Frame: Day 0
|
Surgery time (minutes) was recorded
|
Day 0
|
Wound Healing
Time Frame: Day 10, Weeks 3, 6, 12 and 24
|
A surgeon or a surgical nurse determined if the wound was healed or not healed.
|
Day 10, Weeks 3, 6, 12 and 24
|
Inflammation - Max of Holgers Index
Time Frame: From Day 10 to 12 Months, and to 36 Months
|
Max of Holgers index from day 10 to month 12, and to month 36 was recorded, using the Holgers scale from 0 - 4, where 0 = no inflammation and 4 = removal of abutment/implant necessary due to infection. 0. No irritation
|
From Day 10 to 12 Months, and to 36 Months
|
Inflammation - Holgers Index by Visit
Time Frame: Day 10, Weeks 3, 6, 12, 24, months 12, 24 and 36
|
Infection and inflammation were evaluated by the holgers index at visits 3-10 (Day 10, Weeks 3, 6, 12, 24, months 12, 24 and 36) and the following scale was used: 0. No irritation. Epidermal debris removed, if present
|
Day 10, Weeks 3, 6, 12, 24, months 12, 24 and 36
|
Max Numbness
Time Frame: 12 & 36 months
|
Subjects were asked if they experience any numbness around the abutment at each visit. The maximum numbness each subject experienced is summarized in this analysis. The following scale will be used:
|
12 & 36 months
|
Pain in the Scar and Neuropathic Pain
Time Frame: Day 10, Weeks 3, 6, 12, 24, Months 12 and 36
|
The subject rated the following questions 'has the scar been painful the past few weeks' and 'have you had any neuropathic pain during the past weeks' on the 1-10 scale were 1 = no, not at all and 10 = yes, very much.
|
Day 10, Weeks 3, 6, 12, 24, Months 12 and 36
|
Pain - Maximum of Neuropathic and Scar Pain
Time Frame: 12 months
|
The maximum neuropathic pain and the maximum scar pain experienced at any time throughout the study up until and including 12 months.
|
12 months
|
Pain - Maximum of Neuropathic and Scar Pain
Time Frame: 36 months
|
The maximum neuropathic pain and the maximum scar pain experienced at any time throughout the study up until and including 36 months.
|
36 months
|
Pain by Visit - Categorical
Time Frame: Day 10, Weeks 3, 6, 12, 24, Months 12, 24 and 36
|
The subject rated the following questions 'has the scar been painful the past few weeks' and 'have you had any neuropathic pain during the past weeks' on the 1-10 scale were 1 = no, not at all and 10 = yes, very much. Pain scale was categorised as 1='no pain', 2-3='mild pain', 4-6='moderate pain', 7-10='severe pain'. |
Day 10, Weeks 3, 6, 12, 24, Months 12, 24 and 36
|
Soft Tissue Thickening/Overgrowth
Time Frame: Day 10, Weeks 3, 6, 12, 24, Months 12, 24 and 36
|
The investigator rated the implant site in regards to soft tissue thickening/overgrowth at visits 3-10 according to the following scale: 0. No soft tissue thickening or overgrowth
|
Day 10, Weeks 3, 6, 12, 24, Months 12, 24 and 36
|
Visible Abutment Length by Visit for Patients With no Change of Abutment
Time Frame: Day 10, Weeks 3, 6, 12, 24, Months 12, 24 and 36
|
The investigator measured the visible abutment length at each visit. The length of BA400 test abutments initially placed were longer than BA300 control abutments places. A direct comparison between the groups is not relevant. In some cases of increased soft tissue thickening or overgrowth, the abutment was exchanged for a longer abutment. The results presented here are only for patients with no change of abutment |
Day 10, Weeks 3, 6, 12, 24, Months 12, 24 and 36
|
The Aesthetic Outcome of Surgery, the 'Patient and Observer Scar Assessment Scale' Consisted of Two Parts - a Patient and an Observer Scale, Week 12, Month 12 and 36.
Time Frame: Week 12, Months 12 and 36
|
The patient scale contains six items (pain, itching, color, stiffness, thickness and irregularity) scored 1-10. The observer scale contains six items (vascularity, pigmentation, thickness, relief, pliability and surface area) scored 1-10. Besides the 10-step scale, category boxes are available to score nominal parameters (e.g. type of color). Both patient and observer should also score the overall opinion of the scar on the 1-10 scale. For all above scales 1=normal skin, 10 worst scar imaginable. Total score is the sum of the variables pain, itching, color, stiffness, thickness and irregularity (patient) and vascularity, pigmentation, thickness, relief, pliability and surface area (observer). The scale ranges from 6 to 60 (6 normal, 60 worst scar imaginable). The "pain not with in the scar" variable ranges from 1 to 10. 1 being no pain at all and 10 being very much pain |
Week 12, Months 12 and 36
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Health Utilies Index (HUI-III & HUI-II)
Time Frame: baseline (pre-surgery), week 24, months 12 and 36
|
Health Utilities Index (HUI) is a generic preference-based system for measuring comprehensive health status and health-related quality of life. Each index provides descriptive evidence on multiple dimensions of life quality. HUI3: Comprehensive Health State, Vision, Hearing, Speech, Ambulation, Emotion, Cognition, Pain. HUI2: Comprehensive Health State, Sensation, Mobility, Emotion, Cognition, Self Care, Pain. Subjects completed HUI2/3 questionnaires at visit 1 (baseline), 7 (week 24), 8 (month 12) and 10 (month 36). HUI score of 1 (maximum) describes a state of perfect health. HUI score of 0 describes a state of dead. A negative score of Comprehensive Health State describes a state worse than dead. |
baseline (pre-surgery), week 24, months 12 and 36
|
Abbreviated Profile of Hearing Aid Benefit (APHAB)
Time Frame: Pre-surgery (baseline) to 24 weeks, 12 and 36 months
|
The Abbreviated Profile of Hearing Aid Benefit (APHAB) is a 24-item self-assessment, disability-based inventory that can be used to document the outcome of a hearing aid fitting, to compare several fittings, or to evaluate the same fitting over time. The subjects will complete the APHAB at pre-surgery, week 24, month 12 and 36. Questions assess 'Ease of Communication', 'Background Noise', 'Reverberation', 'Aversiveness', and 'Global' in the aided and unaided situations. The aided situation was compared to the unaided situation at baseline (pre-surgery). For each subscale, a score of 99 indicates that there is 'always' difficulty, and a score of 1 indicated that there is 'never' difficulty for that particular subscale. |
Pre-surgery (baseline) to 24 weeks, 12 and 36 months
|
Use of Sound Processor
Time Frame: Weeks 6, 12, 24, Months 12, 24, 36
|
Use of the sound processor can be seen as a reflection of patient satisfaction and treatment compliance.
Patients were asked to record how many hours per week they used the sound processor after Baha loading at week 3.
|
Weeks 6, 12, 24, Months 12, 24, 36
|
Implant Stability (ISQ)
Time Frame: Surgery, Day 10, Weeks 3, 6, 12, 24, Months 12, 24, 36
|
ISQ is a well-established method to measure stability of osseointegrated implants and has been used for several years both for bone conduction implants and for dental implants. Measurements were performed using resonance frequency analysis at the abutment level. The highest and lowest ISQ value out of two perpendicular measurements obtained at each time point was recorded, ISQ High and ISQ Low. The ISQ values ranges from 1 to 100. Overall, the length of test abutments (BA400) were longer than control abutments (BA300) and there is an inverse correlation between abutment length and stability. A direct comparison between the groups is not relevant. Implant Stability Quotient (ISQ) was recorded at surgery as a baseline value and at visit 2-10. |
Surgery, Day 10, Weeks 3, 6, 12, 24, Months 12, 24, 36
|
Smoking Habits by Visit
Time Frame: baseline, Weeks 3, 12, Months 12, 24 and 36
|
Nicotine use and smoking habits were recorded for patients.
In Sweden a large proportion of adults use another form of tobacco, wet snuff. In Sweden the patients were asked if they used wet snuff. |
baseline, Weeks 3, 12, Months 12, 24 and 36
|
Loss of Implant
Time Frame: from surgery through to 36 months
|
'Loss of Implant' refers to the loss of the implant for reasons including failure of implant to osseointegrate, or an implant that was loose form surgery.
It does not include elected removal of the device.
|
from surgery through to 36 months
|
Removal of Abutment
Time Frame: from surgery through to 36 months
|
Count of subjects who had their abutment removed for reasons of health and safety, such as infection, inflammation or pain.
|
from surgery through to 36 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Robert Stokroos, Professor, NT department, Oxford Building , Peter Debyelaan 25, 6202 AZ Maastricht, The Netherlands
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CBAS5439
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hearing Loss
-
University of California, San FranciscoPatient-Centered Outcomes Research InstituteRecruitingHearing Loss | Hearing Loss, Sensorineural | Hearing Loss, Bilateral | Hearing Loss, Conductive | Hearing Loss, Noise-Induced | Hearing Loss, Unilateral | Hearing Loss, Mixed | Hearing Disorders in ChildrenUnited States
-
Oticon MedicalRecruitingEar Diseases | Hearing Loss, Conductive | Hearing Loss Mixed | Hearing Disability | Conductive Hearing Loss | Conductive Hearing Loss, Bilateral | Conductive Hearing Loss, UnilateralUnited Kingdom
-
MED-EL Elektromedizinische Geräte GesmbHCompletedHearing Loss | Hearing Loss, Sensorineural | Hearing Loss, Bilateral | Hearing Loss, Conductive | Hearing Loss, Unilateral | Hearing Loss, MixedAustria, Germany, United Kingdom
-
Oticon MedicalNot yet recruitingSensorineural Hearing Loss, Bilateral | Sensorineural Hearing Loss, Severe | Sensorineural Hearing Loss, Profound
-
Manchester University NHS Foundation TrustUniversity of ManchesterCompletedCochlear Hearing Loss | Sensorineural Hearing Loss, BilateralUnited Kingdom
-
Oticon MedicalCompletedConductive Hearing Loss | Conductive and Sensori-neural Hearing Loss in the Same Ear | Unilateral, Profound Sensori-neural Hearing LossUnited States
-
Frequency TherapeuticsCompletedHearing Loss, Sensorineural | Presbycusis | Noise Induced Hearing Loss | Sudden Hearing LossUnited States
-
Frequency TherapeuticsCompletedHearing Loss, Sensorineural | Noise Induced Hearing Loss | Sudden Hearing LossUnited States
-
Otologic Pharmaceutics, Inc.CompletedHearing Loss | Sensorineural Hearing Loss | Noise-Induced Hearing LossUnited States
-
Otologics LLCUnknownMixed Conductive and Sensorineural Hearing Loss, Bilateral
Clinical Trials on Minimally invasive surgery and BA400
-
Istituto Clinico HumanitasFondazione Umberto VeronesiRecruiting
-
University of OuluRecruitingEndometriosis | Surgery | Deep EndometriosisFinland
-
National Taiwan University HospitalCompletedColorectal Cancer | AdhesionTaiwan
-
October 6 UniversityCompleted
-
Tianjin Medical University Cancer Institute and...Harvard Medical School (HMS and HSDM); M.D. Anderson Cancer Center; Massachusetts... and other collaboratorsEnrolling by invitation
-
Yarmouk UniversityCompletedMinimally Invasive Surgery | Hydatid Disease | Spleen-Preserving Surgery | Echinococcus Granulosus InfectionJordan
-
Hospital del MarEnrolling by invitationGallbladder CancerSpain
-
University of Illinois at ChicagoRecruiting
-
Yonsei UniversityRecruiting
-
Radboud University Medical CenterDutch Heart Foundation; Penumbra Inc.CompletedIntracerebral Hemorrhage | Surgical Procedures, Minimally InvasiveNetherlands